Cargando…
Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
Autores principales: | Hou, June Y., Rodriguez-Gabin, Alicia, Samaraweera, Leleesha, Hazan, Rachel, Goldberg, Gary L., Horwitz, Susan Band, McDaid, Hayley M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788279/ https://www.ncbi.nlm.nih.gov/pubmed/26967738 http://dx.doi.org/10.1371/journal.pone.0151750 |
Ejemplares similares
-
Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
por: Hou, June Y., et al.
Publicado: (2013) -
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
por: Samaraweera, Leleesha, et al.
Publicado: (2017) -
Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence
por: Chao, Suzan K., et al.
Publicado: (2011) -
Expression of βV-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia
por: Mathew, Deepti, et al.
Publicado: (2018) -
Apigenin Inhibits the Histamine-Induced Proliferation of Ovarian Cancer Cells by Downregulating ERα/ERβ Expression
por: Liu, Manman, et al.
Publicado: (2021)